New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
10:17 EDTDF, PPHM, PHH, HP, BJRIHigh option volume stocks: PHH BJRI HP PPHM DF
News For PHH;BJRI;HP;PPHM;DF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
09:40 EDTBJRIBJ's Restaurants initiated with an Underperform at Tigress Financial
Subscribe for More Information
06:04 EDTDFClean Energy agrees with Dean Foods to construct natural gas station
Clean Energy (CLNE) announced an agreement with Dean Foods (DF) to construct a compressed natural gas station at its Oak Farms Dairy plant in Houston, Texas. Beginning in the second half of 2015, the station will be used to fuel the CNG vehicles deployed by Dean Foods. Over the next several months, Dean Foods will introduce 57 CNG Freightliner M2-112 straight trucks and 7 Freightliner Cascadia over-the-road tractors powered by the Cummins ISL-G and ISX12-G engines, respectively and outfitted with Agility CNG fuel tanks.
March 17, 2015
10:00 EDTBJRIOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:24 EDTBJRIBJ's Restaurants upgraded to Outperform from Neutral at Wedbush
Subscribe for More Information
March 12, 2015
19:29 EDTPPHMPeregrine Phase III SUNRISE trial on track to complete enrollment by year-end
Peregrine Pharmaceuticals provided an update on its advancing clinical pipeline and reviewed other corporate developments. Steven King, president and CEO of Peregrine stated, "This is an exciting time for the company on many fronts. Our lead clinical program, bavituximab is in a unique position as a Phase III immuno-oncology agent that has shown great potential in combination with both current standard cancer treatments, such as chemotherapy, as well as emerging immuno-oncology agents such as those targeting PD-1 and PD-L1. We have continued to advance the bavituximab Phase III SUNRISE trial and are on track to complete enrollment in the study by year-end. Aside from completing enrollment in the SUNRISE trial, our clinical focus is to enter into new clinical collaborations to further explore the combination potential of bavituximab with anti-PD-1 and PD-L1 in multiple tumor indications and we expect these activities to be quite visible over the coming months as the planning that is underway now, comes to fruition. These efforts, on top of completing the Avid capacity expansion and continued revenue growth, point to many important milestones throughout remainder of 2015."
16:02 EDTPPHMPeregrine reports Q3 EPS (8c), consensus (8c)
Reports Q3 revenue $5.68M, consensus $4.23M. The company anticipates completing patient enrollment in the SUNRISE trial by the end of calendar year 2015.
15:27 EDTPPHMNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use